ReviewPharmaceuticals (Basel, Switzerland)2021
PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- Unmasking Early Cardiac Fibrosis in Sarcoidosis: The Role of Plasma Aldosterone and Cardiac MRI.Journal of clinical medicine · 2026Article
- Cardiac Sarcoidosis: Pathophysiology and Diagnostic-Therapeutic Processes.Reviews in cardiovascular medicine · 2026Review
- A Comprehensive Review of SSTR-Based Spect and Pet Imaging in Chronic Inflammatory and Immune-Mediated Diseases.Journal of clinical medicine · 2025Review
- Classic imaging in cardiac sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies.Reviews in cardiovascular medicine · 2025Review
- Multimodality imaging in cardiac sarcoidosis: A case series of diverse phenotypes.Journal of clinical imaging science · 2025Article
- Role of Total Body PET/CT in Inflammatory Disorders.Seminars in nuclear medicine · 2025Review
- Innovations in Imaging:Current cardiology reports · 2024Review
- Can FDG PET Serve as a Clinically Relevant Tool for Detecting Active Non-sarcoidotic Myocarditis?Nuclear medicine and molecular imaging · 2024Review
- A framework for exclusion of alternative diagnoses in sarcoidosis.Journal of autoimmunity · 2024Review
- Review
- The Role of Multimodality Imaging in Cardiomyopathy.Current cardiology reports · 2024Review
- Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests.Rheumatology (Oxford, England) · 2024Review
- Cardiac Sarcoidosis-Diagnostic and Therapeutic Challenges.Journal of clinical medicine · 2024Review
- Exploring the latest advances inAmerican journal of nuclear medicine and molecular imaging · 2024Review
- Cardiac sarcoidosis: diagnosis and management.Frontiers in cardiovascular medicine · 2024Review
- Complete resolution of focal-on-diffuse myocardial activity pattern on FDG PET-CT by prolonging the dietary preparation protocol in cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Biomarkers in Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Updated Review of the Literature.Journal of clinical medicine · 2023Review
- Positron Emission Tomography in Heart Failure: From Pathophysiology to Clinical Application.Journal of cardiovascular development and disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a multi-system inflammatory disease characterized by the development of inflammation and noncaseating granulomas that can involve nearly every organ system, with a predilection for the pulmonary system. Cardiac involvement of sarcoidosis (CS) occurs in up to 70% of cases, and accounts for a significant share of sarcoid-related mortality. The clinical presentation of CS can range from absence of symptoms to conduction abnormalities, heart failure, arrhythmias, valvular disease, and sudden cardiac death. Given the significant morbidity and mortality associated with CS, timely diagnosis is important. Traditional imaging modalities and histologic evaluation by endomyocardial biopsy often provide a low diagnostic yield. Cardiac positron emission tomography (PET) has emerged as a leading advanced imaging modality for the diagnosis and management of CS. This review article will summarize several aspects of the current use of PET in CS, including indications for use, patient preparation, image acquisition and interpretation, diagnostic and prognostic performance, and evaluation of treatment response. Additionally, this review will discuss novel PET radiotracers currently under study or of potential interest in CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.